Idiopathic Pulmonary Fibrosis

July 16, 2015November 5, 2015

Boehringer Ingelheim Lauds 2015 IPF Treatment Guidelines for Recommending OFEV

The recently published 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis – An Update of the 2011 Guideline, which recommends using OFEV® (nintedanib) to treat patients diagnosed with idiopathic pulmonary fibrosis ... Read more

July 15, 2015November 5, 2015

Researchers Uncover A New and Deeper Understanding of Lung Regeneration Pathways

Idiopathic Pulmonary Fibrosis, News

In a new study entitled “Time‐ and compartment‐resolved proteome profiling of the extracellular niche in lung injury and repair,” researchers uncovered the dynamic response of lungs to injury and which ... Read more

July 8, 2015November 5, 2015

Damage To Telomeres Found To Cause Idiopathic Pulmonary Fibrosis in Mice

Idiopathic Pulmonary Fibrosis, News

Researchers at the Spanish National Cancer Centre and Complutense University of Madrid in Spain recently revealed that telomeres, structures that protect chromosomes, are associated with the genesis of idiopathic pulmonary fibrosis. ... Read more

June 30, 2015November 5, 2015

Mechanism of Pulmonary Fibrosis in Rare HPS Patients Identified

Idiopathic Pulmonary Fibrosis, News

Defective responses to physiological insults to the lungs leads to excessive damage and pulmonary fibrosis in the lungs of patients with Hermansky-Pudlak syndrome (HPS), according to a new study from ... Read more

June 19, 2015November 5, 2015

Blocking Autoantibodies Could Treat Severe Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, News

A new study demonstrates that reducing autoantibodies could help treat idiopathic pulmonary fibrosis — particularly in people who have a severe form of the disease. The research, entitled “Autoantibody-Targeted Treatments for Acute Exacerbations ... Read more

June 18, 2015November 5, 2015

UAB Researchers Find Acute Idiopathic Pulmonary Fibrosis Responds to Autoimmune Disease Therapy

Idiopathic Pulmonary Fibrosis, News

In a recent study published in the journal PLOS ONE, researchers from the University of Alabama at Birmingham demonstrated that patients with acute exacerbations of idiopathic pulmonary fibrosis (IPF) responded ... Read more

June 15, 2015November 5, 2015

Study Finds Triciribine Could Reverse Pulmonary Fibrosis and Pulmonary Hypertension Progression

Idiopathic Pulmonary Fibrosis, News

In a recent study published in the British Journal of Pharmacology, researchers at the University of Georgia found that the therapy triciribine could be able to reverse or stop pulmonary hypertension ... Read more

June 12, 2015November 5, 2015

Arrowhead Receives Orphan Drug Designation For Experimental AATD Therapy

Idiopathic Pulmonary Fibrosis, News

Arrowhead Research Corporation, a biopharmaceutical company currently developing targeted RNAi therapeutics, recently announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for its experimental ARC-AAT therapy. ARC-AAT is the company’s RNAi-based therapeutic ... Read more

June 10, 2015November 5, 2015

Baylor Researchers Find That Autophagy Protects Against Lung Inflammation and Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, News

Researchers from Baylor College of Medicine (BCM) recently released study results suggesting that autophagy, a critical immune system component, is necessary to protect against lung inflammation and fibrosis, even in the ... Read more

June 8, 2015November 5, 2015

Promedior Announces Presentation Of Phase 2 Data On IPF Therapy PRM-151 In Treating Myelofibrosis

Idiopathic Pulmonary Fibrosis, News

Promedior Inc. a biotechnology company focused on advancing new therapeutics to address treatment for fibrosis, recently announced that Olga Pozdynakova of Brigham and Women’s Hospital Boston will be presenting further data on the firm’s ongoing Phase 2 clinical trial ... Read more